Summary

Summary

According to APO Research, the global Rare Disease Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Rare Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Rare Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Rare Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Rare Disease Drug include Alexion Pharmaceuticals, Inc., Amgen, Inc., Atara Biotherapeutics, Bayer AG, Biogen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited and Deciphera, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Rare Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare Disease Drug.

The report will help the Rare Disease Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Rare Disease Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rare Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Rare Disease Drug Segment by Company

Alexion Pharmaceuticals, Inc.
Amgen, Inc.
Atara Biotherapeutics
Bayer AG
Biogen, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company Limited
Deciphera
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Novo Nordisk A/S
ProQR
AstraZeneca
GlaxoSmithKline
Pfizer, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis AG
Johnson & Johnson
Sanofi S.A.
Takeda

Rare Disease Drug Segment by Type
Below 0.1‰
Above 1‰
0.65‰～1‰

Rare Disease Drug Segment by Application
Speciality Pharmacies
Hospital Pharmacies
Retail pharmacies
Others

Rare Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rare Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rare Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rare Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

ページTOPに戻る

Table of Contents

1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources

2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Rare Disease Drug Market Size (2020-2031)
2.2.2 Global Rare Disease Drug Sales (2020-2031)
2.2.3 Global Rare Disease Drug Market Average Price (2020-2031)
2.3 Rare Disease Drug by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Below 0.1‰
2.3.3 Above 1‰
2.3.4 0.65‰～1‰
2.4 Rare Disease Drug by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Speciality Pharmacies
2.4.3 Hospital Pharmacies
2.4.4 Retail pharmacies
2.4.5 Others

3 Market Competitive Landscape by Manufacturers
3.1 Global Rare Disease Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Rare Disease Drug Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Rare Disease Drug Revenue of Manufacturers (2020-2025)
3.4 Global Rare Disease Drug Average Price by Manufacturers (2020-2025)
3.5 Global Rare Disease Drug Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Rare Disease Drug, Product Type & Application
3.8 Global Manufacturers of Rare Disease Drug, Established Date
3.9 Global Rare Disease Drug Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled
4.1 Alexion Pharmaceuticals, Inc.
4.1.1 Alexion Pharmaceuticals, Inc. Company Information
4.1.2 Alexion Pharmaceuticals, Inc. Business Overview
4.1.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio
4.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
4.2 Amgen, Inc.
4.2.1 Amgen, Inc. Company Information
4.2.2 Amgen, Inc. Business Overview
4.2.3 Amgen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Amgen, Inc. Rare Disease Drug Product Portfolio
4.2.5 Amgen, Inc. Recent Developments
4.3 Atara Biotherapeutics
4.3.1 Atara Biotherapeutics Company Information
4.3.2 Atara Biotherapeutics Business Overview
4.3.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Atara Biotherapeutics Rare Disease Drug Product Portfolio
4.3.5 Atara Biotherapeutics Recent Developments
4.4 Bayer AG
4.4.1 Bayer AG Company Information
4.4.2 Bayer AG Business Overview
4.4.3 Bayer AG Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Bayer AG Rare Disease Drug Product Portfolio
4.4.5 Bayer AG Recent Developments
4.5 Biogen, Inc.
4.5.1 Biogen, Inc. Company Information
4.5.2 Biogen, Inc. Business Overview
4.5.3 Biogen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Biogen, Inc. Rare Disease Drug Product Portfolio
4.5.5 Biogen, Inc. Recent Developments
4.6 Bristol-Myers Squibb Company
4.6.1 Bristol-Myers Squibb Company Company Information
4.6.2 Bristol-Myers Squibb Company Business Overview
4.6.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio
4.6.5 Bristol-Myers Squibb Company Recent Developments
4.7 Celgene Corporation
4.7.1 Celgene Corporation Company Information
4.7.2 Celgene Corporation Business Overview
4.7.3 Celgene Corporation Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Celgene Corporation Rare Disease Drug Product Portfolio
4.7.5 Celgene Corporation Recent Developments
4.8 Daiichi Sankyo Company Limited
4.8.1 Daiichi Sankyo Company Limited Company Information
4.8.2 Daiichi Sankyo Company Limited Business Overview
4.8.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio
4.8.5 Daiichi Sankyo Company Limited Recent Developments
4.9 Deciphera
4.9.1 Deciphera Company Information
4.9.2 Deciphera Business Overview
4.9.3 Deciphera Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Deciphera Rare Disease Drug Product Portfolio
4.9.5 Deciphera Recent Developments
4.10 Eisai Co., Ltd.
4.10.1 Eisai Co., Ltd. Company Information
4.10.2 Eisai Co., Ltd. Business Overview
4.10.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Eisai Co., Ltd. Rare Disease Drug Product Portfolio
4.10.5 Eisai Co., Ltd. Recent Developments
4.11 F. Hoffmann-La Roche Ltd.
4.11.1 F. Hoffmann-La Roche Ltd. Company Information
4.11.2 F. Hoffmann-La Roche Ltd. Business Overview
4.11.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.11.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio
4.11.5 F. Hoffmann-La Roche Ltd. Recent Developments
4.12 Novo Nordisk A/S
4.12.1 Novo Nordisk A/S Company Information
4.12.2 Novo Nordisk A/S Business Overview
4.12.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Novo Nordisk A/S Rare Disease Drug Product Portfolio
4.12.5 Novo Nordisk A/S Recent Developments
4.13 ProQR
4.13.1 ProQR Company Information
4.13.2 ProQR Business Overview
4.13.3 ProQR Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.13.4 ProQR Rare Disease Drug Product Portfolio
4.13.5 ProQR Recent Developments
4.14 AstraZeneca
4.14.1 AstraZeneca Company Information
4.14.2 AstraZeneca Business Overview
4.14.3 AstraZeneca Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.14.4 AstraZeneca Rare Disease Drug Product Portfolio
4.14.5 AstraZeneca Recent Developments
4.15 GlaxoSmithKline
4.15.1 GlaxoSmithKline Company Information
4.15.2 GlaxoSmithKline Business Overview
4.15.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.15.4 GlaxoSmithKline Rare Disease Drug Product Portfolio
4.15.5 GlaxoSmithKline Recent Developments
4.16 Pfizer, Inc.
4.16.1 Pfizer, Inc. Company Information
4.16.2 Pfizer, Inc. Business Overview
4.16.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Pfizer, Inc. Rare Disease Drug Product Portfolio
4.16.5 Pfizer, Inc. Recent Developments
4.17 Eli Lilly and Company
4.17.1 Eli Lilly and Company Company Information
4.17.2 Eli Lilly and Company Business Overview
4.17.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Eli Lilly and Company Rare Disease Drug Product Portfolio
4.17.5 Eli Lilly and Company Recent Developments
4.18 Merck & Co., Inc.
4.18.1 Merck & Co., Inc. Company Information
4.18.2 Merck & Co., Inc. Business Overview
4.18.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.18.4 Merck & Co., Inc. Rare Disease Drug Product Portfolio
4.18.5 Merck & Co., Inc. Recent Developments
4.19 Novartis AG
4.19.1 Novartis AG Company Information
4.19.2 Novartis AG Business Overview
4.19.3 Novartis AG Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.19.4 Novartis AG Rare Disease Drug Product Portfolio
4.19.5 Novartis AG Recent Developments
4.20 Johnson & Johnson
4.20.1 Johnson & Johnson Company Information
4.20.2 Johnson & Johnson Business Overview
4.20.3 Johnson & Johnson Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.20.4 Johnson & Johnson Rare Disease Drug Product Portfolio
4.20.5 Johnson & Johnson Recent Developments
4.21 Sanofi S.A.
4.21.1 Sanofi S.A. Company Information
4.21.2 Sanofi S.A. Business Overview
4.21.3 Sanofi S.A. Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.21.4 Sanofi S.A. Rare Disease Drug Product Portfolio
4.21.5 Sanofi S.A. Recent Developments
4.22 Takeda
4.22.1 Takeda Company Information
4.22.2 Takeda Business Overview
4.22.3 Takeda Rare Disease Drug Sales, Revenue and Gross Margin (2020-2025)
4.22.4 Takeda Rare Disease Drug Product Portfolio
4.22.5 Takeda Recent Developments

5 Global Rare Disease Drug Market Scenario by Region
5.1 Global Rare Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Rare Disease Drug Sales by Region: 2020-2031
5.2.1 Global Rare Disease Drug Sales by Region: 2020-2025
5.2.2 Global Rare Disease Drug Sales by Region: 2026-2031
5.3 Global Rare Disease Drug Revenue by Region: 2020-2031
5.3.1 Global Rare Disease Drug Revenue by Region: 2020-2025
5.3.2 Global Rare Disease Drug Revenue by Region: 2026-2031
5.4 North America Rare Disease Drug Market Facts & Figures by Country
5.4.1 North America Rare Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Rare Disease Drug Sales by Country (2020-2031)
5.4.3 North America Rare Disease Drug Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Rare Disease Drug Market Facts & Figures by Country
5.5.1 Europe Rare Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Rare Disease Drug Sales by Country (2020-2031)
5.5.3 Europe Rare Disease Drug Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Rare Disease Drug Market Facts & Figures by Country
5.6.1 Asia Pacific Rare Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Rare Disease Drug Sales by Country (2020-2031)
5.6.3 Asia Pacific Rare Disease Drug Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Rare Disease Drug Market Facts & Figures by Country
5.7.1 South America Rare Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Rare Disease Drug Sales by Country (2020-2031)
5.7.3 South America Rare Disease Drug Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Rare Disease Drug Market Facts & Figures by Country
5.8.1 Middle East and Africa Rare Disease Drug Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Rare Disease Drug Sales by Country (2020-2031)
5.8.3 Middle East and Africa Rare Disease Drug Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE

6 Segment by Type
6.1 Global Rare Disease Drug Sales by Type (2020-2031)
6.1.1 Global Rare Disease Drug Sales by Type (2020-2031) & (K Units)
6.1.2 Global Rare Disease Drug Sales Market Share by Type (2020-2031)
6.2 Global Rare Disease Drug Revenue by Type (2020-2031)
6.2.1 Global Rare Disease Drug Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Rare Disease Drug Revenue Market Share by Type (2020-2031)
6.3 Global Rare Disease Drug Price by Type (2020-2031)

7 Segment by Application
7.1 Global Rare Disease Drug Sales by Application (2020-2031)
7.1.1 Global Rare Disease Drug Sales by Application (2020-2031) & (K Units)
7.1.2 Global Rare Disease Drug Sales Market Share by Application (2020-2031)
7.2 Global Rare Disease Drug Revenue by Application (2020-2031)
7.2.1 Global Rare Disease Drug Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Rare Disease Drug Revenue Market Share by Application (2020-2031)
7.3 Global Rare Disease Drug Price by Application (2020-2031)

8 Value Chain and Sales Channels Analysis of the Market
8.1 Rare Disease Drug Value Chain Analysis
8.1.1 Rare Disease Drug Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Rare Disease Drug Production Mode & Process
8.2 Rare Disease Drug Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Rare Disease Drug Distributors
8.2.3 Rare Disease Drug Customers

9 Global Rare Disease Drug Analyzing Market Dynamics
9.1 Rare Disease Drug Industry Trends
9.2 Rare Disease Drug Industry Drivers
9.3 Rare Disease Drug Industry Opportunities and Challenges
9.4 Rare Disease Drug Industry Restraints

10 Report Conclusion
11 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Rare Disease Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global Rare Disease Drug Sales (K Units) of Manufacturers (2020-2025)
Table 7. Global Rare Disease Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Rare Disease Drug Revenue of Manufacturers (2020-2025)
Table 9. Global Rare Disease Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Rare Disease Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
Table 11. Global Rare Disease Drug Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Rare Disease Drug, Product Type & Application
Table 14. Global Rare Disease Drug Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Rare Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Alexion Pharmaceuticals, Inc. Company Information
Table 19. Alexion Pharmaceuticals, Inc. Business Overview
Table 20. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 21. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio
Table 22. Alexion Pharmaceuticals, Inc. Recent Developments
Table 23. Amgen, Inc. Company Information
Table 24. Amgen, Inc. Business Overview
Table 25. Amgen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 26. Amgen, Inc. Rare Disease Drug Product Portfolio
Table 27. Amgen, Inc. Recent Developments
Table 28. Atara Biotherapeutics Company Information
Table 29. Atara Biotherapeutics Business Overview
Table 30. Atara Biotherapeutics Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 31. Atara Biotherapeutics Rare Disease Drug Product Portfolio
Table 32. Atara Biotherapeutics Recent Developments
Table 33. Bayer AG Company Information
Table 34. Bayer AG Business Overview
Table 35. Bayer AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 36. Bayer AG Rare Disease Drug Product Portfolio
Table 37. Bayer AG Recent Developments
Table 38. Biogen, Inc. Company Information
Table 39. Biogen, Inc. Business Overview
Table 40. Biogen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 41. Biogen, Inc. Rare Disease Drug Product Portfolio
Table 42. Biogen, Inc. Recent Developments
Table 43. Bristol-Myers Squibb Company Company Information
Table 44. Bristol-Myers Squibb Company Business Overview
Table 45. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 46. Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio
Table 47. Bristol-Myers Squibb Company Recent Developments
Table 48. Celgene Corporation Company Information
Table 49. Celgene Corporation Business Overview
Table 50. Celgene Corporation Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 51. Celgene Corporation Rare Disease Drug Product Portfolio
Table 52. Celgene Corporation Recent Developments
Table 53. Daiichi Sankyo Company Limited Company Information
Table 54. Daiichi Sankyo Company Limited Business Overview
Table 55. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 56. Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio
Table 57. Daiichi Sankyo Company Limited Recent Developments
Table 58. Deciphera Company Information
Table 59. Deciphera Business Overview
Table 60. Deciphera Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 61. Deciphera Rare Disease Drug Product Portfolio
Table 62. Deciphera Recent Developments
Table 63. Eisai Co., Ltd. Company Information
Table 64. Eisai Co., Ltd. Business Overview
Table 65. Eisai Co., Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 66. Eisai Co., Ltd. Rare Disease Drug Product Portfolio
Table 67. Eisai Co., Ltd. Recent Developments
Table 68. F. Hoffmann-La Roche Ltd. Company Information
Table 69. F. Hoffmann-La Roche Ltd. Business Overview
Table 70. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 71. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio
Table 72. F. Hoffmann-La Roche Ltd. Recent Developments
Table 73. Novo Nordisk A/S Company Information
Table 74. Novo Nordisk A/S Business Overview
Table 75. Novo Nordisk A/S Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Novo Nordisk A/S Rare Disease Drug Product Portfolio
Table 77. Novo Nordisk A/S Recent Developments
Table 78. ProQR Company Information
Table 79. ProQR Business Overview
Table 80. ProQR Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. ProQR Rare Disease Drug Product Portfolio
Table 82. ProQR Recent Developments
Table 83. AstraZeneca Company Information
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. AstraZeneca Rare Disease Drug Product Portfolio
Table 87. AstraZeneca Recent Developments
Table 88. GlaxoSmithKline Company Information
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. GlaxoSmithKline Rare Disease Drug Product Portfolio
Table 92. GlaxoSmithKline Recent Developments
Table 93. Pfizer, Inc. Company Information
Table 94. Pfizer, Inc. Business Overview
Table 95. Pfizer, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Pfizer, Inc. Rare Disease Drug Product Portfolio
Table 97. Pfizer, Inc. Recent Developments
Table 98. Eli Lilly and Company Company Information
Table 99. Eli Lilly and Company Business Overview
Table 100. Eli Lilly and Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Eli Lilly and Company Rare Disease Drug Product Portfolio
Table 102. Eli Lilly and Company Recent Developments
Table 103. Merck & Co., Inc. Company Information
Table 104. Merck & Co., Inc. Business Overview
Table 105. Merck & Co., Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Merck & Co., Inc. Rare Disease Drug Product Portfolio
Table 107. Merck & Co., Inc. Recent Developments
Table 108. Novartis AG Company Information
Table 109. Novartis AG Business Overview
Table 110. Novartis AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Novartis AG Rare Disease Drug Product Portfolio
Table 112. Novartis AG Recent Developments
Table 113. Johnson & Johnson Company Information
Table 114. Johnson & Johnson Business Overview
Table 115. Johnson & Johnson Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Johnson & Johnson Rare Disease Drug Product Portfolio
Table 117. Johnson & Johnson Recent Developments
Table 118. Sanofi S.A. Company Information
Table 119. Sanofi S.A. Business Overview
Table 120. Sanofi S.A. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Sanofi S.A. Rare Disease Drug Product Portfolio
Table 122. Sanofi S.A. Recent Developments
Table 123. Takeda Company Information
Table 124. Takeda Business Overview
Table 125. Takeda Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Takeda Rare Disease Drug Product Portfolio
Table 127. Takeda Recent Developments
Table 128. Global Rare Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 129. Global Rare Disease Drug Sales by Region (2020-2025) & (K Units)
Table 130. Global Rare Disease Drug Sales Market Share by Region (2020-2025)
Table 131. Global Rare Disease Drug Sales by Region (2026-2031) & (K Units)
Table 132. Global Rare Disease Drug Sales Market Share by Region (2026-2031)
Table 133. Global Rare Disease Drug Revenue by Region (2020-2025) & (US$ Million)
Table 134. Global Rare Disease Drug Revenue Market Share by Region (2020-2025)
Table 135. Global Rare Disease Drug Revenue by Region (2026-2031) & (US$ Million)
Table 136. Global Rare Disease Drug Revenue Market Share by Region (2026-2031)
Table 137. North America Rare Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 138. North America Rare Disease Drug Sales by Country (2020-2025) & (K Units)
Table 139. North America Rare Disease Drug Sales by Country (2026-2031) & (K Units)
Table 140. North America Rare Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 141. North America Rare Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 142. Europe Rare Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 143. Europe Rare Disease Drug Sales by Country (2020-2025) & (K Units)
Table 144. Europe Rare Disease Drug Sales by Country (2026-2031) & (K Units)
Table 145. Europe Rare Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 146. Europe Rare Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 147. Asia Pacific Rare Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 148. Asia Pacific Rare Disease Drug Sales by Country (2020-2025) & (K Units)
Table 149. Asia Pacific Rare Disease Drug Sales by Country (2026-2031) & (K Units)
Table 150. Asia Pacific Rare Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 151. Asia Pacific Rare Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 152. South America Rare Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 153. South America Rare Disease Drug Sales by Country (2020-2025) & (K Units)
Table 154. South America Rare Disease Drug Sales by Country (2026-2031) & (K Units)
Table 155. South America Rare Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 156. South America Rare Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 157. Middle East and Africa Rare Disease Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 158. Middle East and Africa Rare Disease Drug Sales by Country (2020-2025) & (K Units)
Table 159. Middle East and Africa Rare Disease Drug Sales by Country (2026-2031) & (K Units)
Table 160. Middle East and Africa Rare Disease Drug Revenue by Country (2020-2025) & (US$ Million)
Table 161. Middle East and Africa Rare Disease Drug Revenue by Country (2026-2031) & (US$ Million)
Table 162. Global Rare Disease Drug Sales by Type (2020-2025) & (K Units)
Table 163. Global Rare Disease Drug Sales by Type (2026-2031) & (K Units)
Table 164. Global Rare Disease Drug Sales Market Share by Type (2020-2025)
Table 165. Global Rare Disease Drug Sales Market Share by Type (2026-2031)
Table 166. Global Rare Disease Drug Revenue by Type (2020-2025) & (US$ Million)
Table 167. Global Rare Disease Drug Revenue by Type (2026-2031) & (US$ Million)
Table 168. Global Rare Disease Drug Revenue Market Share by Type (2020-2025)
Table 169. Global Rare Disease Drug Revenue Market Share by Type (2026-2031)
Table 170. Global Rare Disease Drug Price by Type (2020-2025) & (US$/Unit)
Table 171. Global Rare Disease Drug Price by Type (2026-2031) & (US$/Unit)
Table 172. Global Rare Disease Drug Sales by Application (2020-2025) & (K Units)
Table 173. Global Rare Disease Drug Sales by Application (2026-2031) & (K Units)
Table 174. Global Rare Disease Drug Sales Market Share by Application (2020-2025)
Table 175. Global Rare Disease Drug Sales Market Share by Application (2026-2031)
Table 176. Global Rare Disease Drug Revenue by Application (2020-2025) & (US$ Million)
Table 177. Global Rare Disease Drug Revenue by Application (2026-2031) & (US$ Million)
Table 178. Global Rare Disease Drug Revenue Market Share by Application (2020-2025)
Table 179. Global Rare Disease Drug Revenue Market Share by Application (2026-2031)
Table 180. Global Rare Disease Drug Price by Application (2020-2025) & (US$/Unit)
Table 181. Global Rare Disease Drug Price by Application (2026-2031) & (US$/Unit)
Table 182. Key Raw Materials
Table 183. Raw Materials Key Suppliers
Table 184. Rare Disease Drug Distributors List
Table 185. Rare Disease Drug Customers List
Table 186. Rare Disease Drug Industry Trends
Table 187. Rare Disease Drug Industry Drivers
Table 188. Rare Disease Drug Industry Restraints
Table 189. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Rare Disease Drug Product Image
Figure 5. Global Rare Disease Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global Rare Disease Drug Market Size (2020-2031) & (US$ Million)
Figure 7. Global Rare Disease Drug Sales (2020-2031) & (K Units)
Figure 8. Global Rare Disease Drug Average Price (US$/Unit) & (2020-2031)
Figure 9. Below 0.1‰ Product Image
Figure 10. Above 1‰ Product Image
Figure 11. 0.65‰～1‰ Product Image
Figure 12. Speciality Pharmacies Product Image
Figure 13. Hospital Pharmacies Product Image
Figure 14. Retail pharmacies Product Image
Figure 15. Others Product Image
Figure 16. Global Rare Disease Drug Revenue Share by Manufacturers in 2024
Figure 17. Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters
Figure 18. Global Top 5 and 10 Rare Disease Drug Players Market Share by Revenue in 2024
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Rare Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. Global Rare Disease Drug Sales by Region in 2024
Figure 22. Global Rare Disease Drug Revenue by Region in 2024
Figure 23. North America Rare Disease Drug Market Size by Country in 2024
Figure 24. North America Rare Disease Drug Sales Market Share by Country (2020-2031)
Figure 25. North America Rare Disease Drug Revenue Market Share by Country (2020-2031)
Figure 26. United States Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Rare Disease Drug Market Size by Country in 2024
Figure 29. Europe Rare Disease Drug Sales Market Share by Country (2020-2031)
Figure 30. Europe Rare Disease Drug Revenue Market Share by Country (2020-2031)
Figure 31. Germany Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Netherlands Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Rare Disease Drug Market Size by Country in 2024
Figure 37. Asia Pacific Rare Disease Drug Sales Market Share by Country (2020-2031)
Figure 38. Asia Pacific Rare Disease Drug Revenue Market Share by Country (2020-2031)
Figure 39. China Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. China Taiwan Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. South America Rare Disease Drug Market Size by Country in 2024
Figure 48. South America Rare Disease Drug Sales Market Share by Country (2020-2031)
Figure 49. South America Rare Disease Drug Revenue Market Share by Country (2020-2031)
Figure 50. Mexico Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Brazil Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Argentina Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Middle East and Africa Rare Disease Drug Market Size by Country in 2024
Figure 54. Middle East and Africa Rare Disease Drug Sales Market Share by Country (2020-2031)
Figure 55. Middle East and Africa Rare Disease Drug Revenue Market Share by Country (2020-2031)
Figure 56. Turkey Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. UAE Rare Disease Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Global Rare Disease Drug Sales Market Share by Type (2020-2031)
Figure 60. Global Rare Disease Drug Revenue Market Share by Type (2020-2031)
Figure 61. Global Rare Disease Drug Price (US$/Unit) by Type (2020-2031)
Figure 62. Global Rare Disease Drug Sales Market Share by Application (2020-2031)
Figure 63. Global Rare Disease Drug Revenue Market Share by Application (2020-2031)
Figure 64. Global Rare Disease Drug Price (US$/Unit) by Application (2020-2031)
Figure 65. Rare Disease Drug Value Chain
Figure 66. Rare Disease Drug Production Mode & Process
Figure 67. Direct Comparison with Distribution Share
Figure 68. Distributors Profiles
Figure 69. Rare Disease Drug Industry Opportunities and Challenges